Melanoma Clinical Trials in Phoenix

Showing 81-100 of 238 trials

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

NCT02680184

This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available to those who are currently being treated in either Part 1 or Part 2 of this study at the time of protocol Amendment 9, v10.0.

Melanoma

Regeneron Pharmaceuticals199 participantsStarted Apr 2016

Phoenix, Arizona, United States • Tucson, Arizona, United States • Duarte, California, United States +10 more locations

RECRUITINGPhase 2< 1 mile

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

NCT04291105

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.

MelanomaHead and Neck Squamous Cell CarcinomaColo-rectal Cancer

Vyriad, Inc.87 participantsStarted Apr 2020

Phoenix, Arizona, United States • Durate, California, United States • Los Angeles, California, United States +24 more locations

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Melanoma Trials in Other Cities

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Education for Prevention of Melanoma in Hispanic Populations

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

A Study of SEA-CD40 Given With Other Drugs in Cancers

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

A Study to Investigate LYL845 in Adults With Solid Tumors

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Other Conditions in Phoenix